EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modulators of epithelial-mesenchymal transitions in prostate cancer: potential for novel therapeutics development

Jinxia Zheng, Ling Li, Holly Russell, Duygu Duzgun, Sebastian Oltean

Frontiers in Pharmacology · 18.08.2026 · 17

DOI: 10.3389/fphar.2026.1808307 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 18.08.2026. Verfasst von Jinxia Zheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, United Kingdom. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Research in the area of hallmarks of cancer has opened the possibility of designing novel therapeutic interventions based on modulating cancer properties. Interestingly, the epithelial-mesenchymal transition (EMT), important in both tumour growth and metastasis, has not been targeted in prostate cancer (PCa). Previously, in a repositioning screen, three new chemicals that modulate EMT in PCa (LLSO1 - NNC-55-0396 dihydrochloride; LLSO2 - Nemadipine A; LLSO3 - Naltrexone hydrochloride) have been found. This study aims to investigate how they work mechanistically as well as the effect of these LLSOs on the properties of PCa cells both in vitro and in vivo . Although these LLSOs exhibited varying effects on different cancer cell lines, all of them modulated EMT by inhibiting the migration of PCa cells. LLSO3 also exhibited a significant inhibitory effect on tumour growth in vivo , concomitant with an increase in the expression levels of E-cadherin. Further investigation was conducted to obtain mechanistic insights into the LLSO compounds mode of action. In conclusion, our work strongly supports that LLSO compounds may become important candidates for targeted therapeutics in prostate cancer.

Schlagwörter

Stichwörter der Autor:innen

E-cadherinN-cadherincancer cell migrationepithelial-mesenchymal transitionsnaltrexone hydrochloridenovel therapeuticsprostate cancer

Autor:innen und Institutionen

  • Department of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, United Kingdom.

Zitieren

APA

Zheng, J., Li, L., Russell, H., Duzgun, D., & Oltean, S. (2026). Modulators of epithelial-mesenchymal transitions in prostate cancer: potential for novel therapeutics development. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1808307

Vancouver

Zheng J, Li L, Russell H, Duzgun D, Oltean S. Modulators of epithelial-mesenchymal transitions in prostate cancer: potential for novel therapeutics development. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1808307

BibTeX
@article{Zheng2026,
  author = {Zheng, Jinxia and Li, Ling and Russell, Holly and Duzgun, Duygu and Oltean, Sebastian},
  title = {Modulators of epithelial-mesenchymal transitions in prostate cancer: potential for novel therapeutics development},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1808307}
}
Kostenlos starten →